Drosophila melanogaster experimental model to test new antimicrobials : a methodological approach
Vidal, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Arch Sisquella, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fuentes, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cardona, Pere-Joan (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)

Date:	2024
Abstract:	Given the increasing concern about antimicrobial resistance among the microorganisms that cause infections in our society, there is an urgent need for new drug discovery. Currently, this process involves testing many low-quality compounds, resulting from the in vivo testing, on mammal models, which not only wastes time, resources, and money, but also raises ethical questions. In this review, we have discussed the potential of D. melanogaster as an intermediary experimental model in this drug discovery timeline. We have tackled the topic from a methodological perspective, providing recommendations regarding the range of drug concentrations to test based on the mechanism of action of each compound; how to treat D. melanogaster, how to monitor that treatment, and what parameters we should consider when designing a drug screening protocol to maximize the study's benefits. We also discuss the necessary improvements needed to establish the D. melanogaster model of infection as a standard technique in the drug screening process. Overall, D. melanogaster has been demonstrated to be a manageable model for studying broad-spectrum infection treatment. It allows us to obtain valuable information in a cost-effective manner, which can improve the drug screening process and provide insights into our current major concern. This approach is also in line with the 3R policy in biomedical research, in particular on the replacement and reduce the use of vertebrates in preclinical development.
Grants:	European Commission 101080462 "la Caixa" Foundation LCF/PR/GN16/10290002 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00931 Instituto de Salud Carlos III PI20/01431
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Drosophila melanogaster ; Antimicrobials ; Resistance ; Screening ; 3R policy ; Innate immunity ; Host-directed therapies ; Preclinical
Published in:	Frontiers in microbiology, Vol. 15 (November 2024) , ISSN 1664-302X

DOI: 10.3389/fmicb.2024.1478263
PMID: 39568995

17 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles